News


Melinta Therapeutics Presenting Detailed Analyses from Baxdela Phase 3 ABSSSI Trials and In Vitro Performance against Isolates of Resistant CABP and other Infections

Melinta Therapeutics, a privately held company developing and commercializing novel antibiotics to treat serious bacterial infections, announced that it will be making nine poster presentations and participating in an oral session at the upcoming IDWeek 2017 annual scientific meeting. These presentations will provide detailed analyses of the safety and efficacy results from the two Phase 3 studies of Baxdela™ (delafloxacin) in the treatment of patients with acute bacterial skin and skin structure infections (ABSSSI). In addition, in vitro findings characterizing Baxdela’s activity against pathogens associated with community-acquired respiratory tract infections will be presented.